How India Exports Phenylephrine to the World

In the United States, phenylephrine is approved for various indications, including as a nasal decongestant and for ophthalmic use. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for phenylephrine products, reflecting its established presence in the market. Notably, on March 21, 2013, the FDA approved Paragon BioTeck, Inc.'s New Drug Application (NDA) 203510 for Phenylephrine Hydrochloride Ophthalmic Solution at concentrations of 2.5% and 10%.

The regulatory pathway for phenylephrine involves compliance with the FDA's monograph system for over-the-counter (OTC) drugs. In August 1994, the FDA issued a final rule establishing conditions under which OTC nasal decongestant drug products, including oral phenylephrine, are generally recognized as safe and effective. Given that 50.8% of India's phenylephrine exports are directed to the U.S., Indian exporters must ensure adherence to these regulatory standards to maintain market access.

In the European Union, phenylephrine is subject to marketing authorization by the European Medicines Agency (EMA). For instance, Omidria, a combination product containing phenylephrine and ketorolac, received EMA approval on July 28, 2015, for use in intraocular lens replacement surgery. (ema.europa.eu) Additionally, phenylephrine hydrochloride was granted orphan designation on November 20, 2001, for the treatment of ileal pouch anal anastomosis-related fecal incontinence. (ema.europa.eu)

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of phenylephrine-containing products. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions.

Phenylephrine is included in the World Health Organization's Model List of Essential Medicines, underscoring its significance in global health. It is also recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different markets.

In India, phenylephrine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing; however, as of March 2026, phenylephrine is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

Phenylephrine is a well-established pharmaceutical agent with no active patents or exclusivity rights, facilitating robust generic competition. This competitive landscape is reflected in India's export data, with 541 active exporters and an average Free on Board (FOB) unit price of $6.26.

In November 2024, the FDA issued a proposed administrative order to amend the OTC monograph for cold, cough, allergy, bronchodilator, and antiasthmatic drug products, proposing the removal of orally administered phenylephrine hydrochloride and phenylephrine bitartrate in effervescent dosage forms as nasal decongestant active ingredients due to efficacy concerns.

In July 2024, the EMA conducted a periodic safety update report single assessment (PSUSA) for phenylephrine-containing products, resulting in a maintenance decision, indicating no significant safety concerns. (ema.europa.eu)

In August 2024, the NPPA reviewed the pricing of various pharmaceutical products, including phenylephrine formulations, but no price ceiling was imposed, allowing market-driven pricing to continue.

In December 2024, the DGFT streamlined the export NOC process for pharmaceutical products, reducing processing times by 20%, thereby facilitating more efficient export operations for phenylephrine manufacturers.

In February 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of phenylephrine, highlighting its continued importance in global healthcare.

These developments underscore the dynamic regulatory environment surrounding phenylephrine, necessitating continuous monitoring by stakeholders to ensure compliance and market competitiveness.

India's pharmaceutical industry, renowned as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of KSMs are imported from China, making India vulnerable to supply chain disruptions. This dependency became evident during the COVID-19 pandemic when Chinese factory shutdowns led to immediate shortages and price surges in common drugs.

To mitigate this risk, the Indian government launched the Production Linked Incentive (PLI) scheme in October 2024, aiming to bolster domestic production of critical APIs and KSMs. Two greenfield plants were inaugurated under this initiative to manufacture essential molecules like Penicillin G and Clavulanic Acid, which had not been produced domestically for over two decades. Despite these efforts, reducing dependence on Chinese imports remains a significant challenge.

Our proprietary trade data indicates that the top five exporters of phenylephrine from India account for 46.1% of total exports, with MANKIND PHARMA LIMITED alone contributing 28.3%. This concentration poses a risk, as disruptions affecting these key suppliers could significantly impact global phenylephrine availability.

The PLI scheme, initiated in October 2024, aims to diversify the supplier base by encouraging more manufacturers to produce critical APIs and KSMs domestically. While this initiative has led to increased investment, the effectiveness in reducing supplier concentration is yet to be fully realized.

Recent geopolitical tensions have severely impacted global shipping routes. In February 2026, the closure of the Strait of Hormuz following US and Israeli airstrikes on Iran disrupted the supply of raw materials to Asia's petrochemical industry, leading to force majeure declarations and production cutbacks. Additionally, attacks in the Red Sea have caused shipping giants to suspend routes, further straining supply chains.

These disruptions have led to increased freight costs and delays, affecting the timely delivery of APIs and KSMs necessary for phenylephrine production. While the FDA has not issued specific shortage alerts for phenylephrine, the potential for future shortages remains if these geopolitical tensions persist.

• Diversify Supplier Base: Encourage the development of alternative suppliers for phenylephrine and its raw materials to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to boost domestic manufacturing of critical APIs and KSMs, thereby decreasing dependence on imports.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to detect early signs of supply chain disruptions, enabling proactive measures to mitigate risks.

• Develop Contingency Plans: Establish comprehensive contingency plans, including alternative shipping routes and strategic stockpiling, to ensure continuity of supply during geopolitical crises.

• Engage in International Collaboration: Foster partnerships with international regulatory bodies and industry stakeholders to share information and coordinate responses to global supply chain challenges.

RISK_LEVEL: HIGH